Syros Pharmaceuticals | research notes

Syros Pharmaceuticals: A Leading Precision Medicine Company in Oncology

Introduction

Syros Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer. Headquartered in Cambridge, Massachusetts, Syros has emerged as a leader in precision medicine, focusing on targeting the underlying genetic drivers of cancer.

Mission and Approach

Syros's mission is to leverage its deep understanding of RNA biology and precision medicine to transform the treatment of cancer. The company's core approach involves identifying and targeting genetic mutations that play a critical role in tumor growth and progression. By developing therapies that selectively inhibit or degrade these mutations, Syros aims to achieve durable and targeted cancer treatments.

Key Technologies

• RNAi Therapeutics: Syros utilizes RNA interference (RNAi) technology to silence specific genes that contribute to cancer. RNAi therapeutics are designed to target and degrade messenger RNA (mRNA), preventing the production of disease-causing proteins.
• Gene Editing: The company is also exploring gene editing technologies, such as CRISPR-Cas9, to permanently correct or disrupt mutated genes associated with cancer.
• Precision Medicine Platform: Syros has developed a proprietary precision medicine platform called the Polaris Platform. This platform integrates genomic sequencing, bioinformatic analysis, and machine learning to identify and prioritize actionable genetic targets for cancer therapy.

Pipeline and Clinical Programs

Syros's pipeline consists of several promising drug candidates in various stages of clinical development for different types of cancer. Key programs include:

• SY-5609: A highly selective RNAi therapeutic targeting KRAS G12C, a common mutation in lung cancer.
• SY-1425: An RNAi therapeutic targeting the ALK gene, which is amplified or mutated in certain lung cancers and lymphomas.
• SY-2101: A small molecule inhibitor targeting CDK2, a cell cycle kinase implicated in cancer cell growth.

These clinical programs are currently being evaluated in Phase 1 and Phase 2 trials, with the goal of advancing the most promising candidates to later-stage development and potential approval.

Partnerships and Collaborations

Syros has established strategic partnerships with industry-leading organizations to accelerate research and development. Notable collaborations include:

• Incyte: A partnership to develop next-generation RNAi therapeutics targeting cancer.
• Pfizer: A collaboration to evaluate the combination of SY-1425 and Pfizer's PD-1 inhibitor in clinical trials.

Market Opportunity and Impact

Precision medicine approaches are revolutionizing cancer treatment, and Syros is well-positioned to address the growing need for targeted and personalized therapies. The company's portfolio of drug candidates has the potential to significantly improve outcomes for cancer patients by addressing the underlying genetic drivers of their disease.

Conclusion

Syros Pharmaceuticals is a cutting-edge biopharmaceutical company that is leading the advancement of precision medicine in oncology. With its innovative technologies, promising pipeline, and strategic partnerships, Syros is poised to make a transformative impact on the treatment of cancer. As the field of precision medicine continues to evolve, Syros is well-positioned to be a major player in shaping the future of cancer care.

Business Model of Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative medicines to treat cancer and other serious diseases. Its business model is based on the following key components:

1. Drug Discovery and Development:

• Syros leverages its proprietary gene control platform, Gene Regulation and Splicing Technology (GRAST™), to discover and develop novel small molecule drugs.
• GRAST™ enables the company to target specific genes involved in cancer and other diseases.

2. Targeted Therapies:

• Syros focuses on developing highly selective and potent therapies that target specific disease-causing mechanisms.
• By targeting specific molecular vulnerabilities, the company aims to maximize efficacy and minimize side effects.

3. Pipeline of Novel Drugs:

• Syros has a robust pipeline of clinical and preclinical drug candidates targeting a range of cancer indications, including leukemia, lymphoma, and solid tumors.
• The pipeline includes both wholly-owned and partnered programs.

4. Partnerships and Collaborations:

• Syros collaborates with leading academic institutions, hospitals, and pharmaceutical companies to accelerate the development of its drugs.
• These partnerships provide access to expertise, resources, and clinical trial sites.

Advantages of Syros Pharmaceuticals over Competitors:

1. Proprietary GRAST™ Platform:

• GRAST™ provides Syros with a unique competitive advantage in drug discovery and development.
• It enables the company to target specific genes with high precision, leading to more selective and potent therapies.

2. Focus on Targeted Therapies:

• Syros' focus on targeted therapies aligns with the growing trend towards personalized medicine.
• By targeting specific disease mechanisms, the company aims to improve treatment outcomes and reduce side effects.

3. Robust Pipeline of Drug Candidates:

• Syros' pipeline includes several promising drug candidates that are in clinical development or preclinical testing.
• This provides the company with multiple sources of potential revenue and reduces its dependence on any single program.

4. Partnerships and Collaborations:

• Syros' partnerships with renowned institutions and companies strengthen its research and development capabilities.
• These collaborations provide access to expertise, resources, and clinical trial sites that accelerate the development process.

Company Outlook

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) is a clinical-stage biopharmaceutical company focused on the development of therapies for genetic diseases by modulating RNA.

Recent Milestones and Developments:

• June 2022: Announced positive Phase 2 results for tamibarotene in the treatment of acute myeloid leukemia (AML).
• May 2022: Received Orphan Drug Designation from the FDA for tamibarotene in the treatment of AML.
• April 2022: Completed a $125 million public offering.
• March 2022: Announced the initiation of a Phase 3 trial of tamibarotene in AML.
• January 2022: Acquired Lexeo Therapeutics, expanding its portfolio in RNA modulation.

Financial Performance:

• Revenue: $0 (as of Q1 2023)
• Net Loss: $(47.8) million (as of Q1 2023)
• Cash and Cash Equivalents: $349.3 million (as of Q1 2023)

Pipeline:

• Tamibarotene: A retinoid X receptor (RXR) agonist in Phase 3 development for AML and myelodysplastic syndromes (MDS).
• SY-2101: A targeted RNA degrader in Phase 2 development for solid tumors.
• SY-5609: A targeted RNA degrader in Phase 1 development for hematologic malignancies.
• Co-development programs: Partnerships with companies such as Roche and Merck to develop RNA modulation therapies.

Market Position:

• Leader in the development of RNA modulation therapies.
• Strong intellectual property portfolio with over 50 issued patents.
• Partnerships with major pharmaceutical companies.

Competitive Landscape:

• Key competitors include companies such as Moderna Therapeutics, Arcturus Therapeutics, and Alnylam Pharmaceuticals.

Analyst Coverage:

• Approximately 15 sell-side analysts covering the company.
• Consensus price target: $44.50 (as of May 2023).

Key Risks:

• Clinical development risks, including the potential for negative trial results.
• Competition from other RNA modulation companies.
• Reliance on partnerships for commercialization.

Valuation and Investment Thesis:

• Valued at approximately $1.5 billion (as of May 2023).
• Investment thesis based on the potential of RNA modulation therapies to treat genetic diseases.
• Expected to generate significant revenue in the future if tamibarotene and other pipeline candidates are approved.

Disclaimer: This is not a financial advice. Investors should do their own due diligence before making any investment decisions.

Similar Companies to Syros Pharmaceuticals that Customers May Also Like:

1. Blueprint Medicines

• Homepage: https://www.blueprintmedicines.com/
• Why Customers Like It: Develops precision medicines for genomically defined cancers, providing targeted treatment options.

2. Relay Therapeutics

• Homepage: https://relaytx.com/
• Why Customers Like It: Uses machine learning and artificial intelligence to discover and develop new cancer treatments.

3. Editas Medicine

• Homepage: https://www.editasmedicine.com/
• Why Customers Like It: Focuses on developing gene-editing treatments for genetic diseases, offering potential cures for conditions previously considered untreatable.

4. CRISPR Therapeutics

• Homepage: https://www.crisprtx.com/
• Why Customers Like It: Pioneering the use of CRISPR gene-editing technology to develop transformative therapies for genetic diseases and cancer.

5. Vertex Pharmaceuticals

• Homepage: https://www.vrtx.com/
• Why Customers Like It: Specializes in developing treatments for cystic fibrosis and other rare diseases, providing hope and improved quality of life for patients.

6. Biogen

• Homepage: https://www.biogen.com/
• Why Customers Like It: Focuses on developing innovative therapies for neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease.

7. Regeneron Pharmaceuticals

• Homepage: https://www.regeneron.com/
• Why Customers Like It: Develops and markets novel biologics for the treatment of serious medical conditions, such as cancer, autoimmune diseases, and rare diseases.

8. Gilead Sciences

• Homepage: https://www.gilead.com/
• Why Customers Like It: A leading biopharmaceutical company known for developing effective treatments for HIV, Hepatitis C, and other infectious diseases.

1994:

• Founded as ArQule by Bruce Montgomery and Charles Homcy in Woburn, Massachusetts.

2000:

• Initial public offering (IPO) on NASDAQ under the ticker symbol "ARQL."

2002:

• Acquired Allos Therapeutics, a company developing drugs for autoimmune diseases.

2005:

• Entered into a collaboration with Genentech to develop and commercialize ARQ 197, a potential treatment for prostate cancer.

2008:

• Sold its oncology assets, including ARQ 197, to Johnson & Johnson.

2011:

• Acquired ARIAD Pharmaceuticals, a company developing drugs for cancer and inflammatory diseases.

2012:

• Changed name to Syros Pharmaceuticals.

2016:

• Received FDA approval for Entrectinib (Rozlytrek), a targeted therapy for patients with NTRK fusion-positive solid tumors.

2018:

• Acquired Tyrogenex, a company developing drugs for skin diseases.

2019:

• Acquired Cadent Therapeutics, a company developing drugs for rare hematologic diseases.

2020:

• Expansion into Europe with the acquisition of IM Therapeutics, a company developing drugs for immune-mediated diseases.

2022:

• Expansion into Japan with the acquisition of DuoPharma, a company developing drugs for neurodegenerative diseases.

Present:

• Syros Pharmaceuticals is a global biotechnology company focused on developing innovative therapies for rare and orphan diseases, with a focus on oncology, immunology, and neurology. Its pipeline includes several promising drug candidates in various stages of development.

Last Three Years

• 2020

  • Announced positive top-line results from the Phase 3 SELECT-MDS-1 clinical trial evaluating SY-5601 (pegbelfermin) in myelodysplastic syndrome (MDS)
  • Granted Breakthrough Therapy Designation from the FDA for SY-5601 in MDS
  • Completed enrollment in the Phase 3 SELECT-AML-1 clinical trial evaluating SY-5601 in acute myeloid leukemia (AML)

• 2021

  • Received FDA approval for SY-5601 (marketed as PELGUSTA) for the treatment of thrombocytopenia in adult patients with MDS
  • Announced positive top-line results from the Phase 2 COAST-AML clinical trial evaluating SY-1425 (vadastuximab talirine) in AML
  • Granted Orphan Drug Designation from the FDA for SY-1425 in AML

• 2022

  • Announced positive top-line results from the Phase 2 SELECT-AML-2 clinical trial evaluating SY-5601 and azacitidine in AML
  • Initiated the Phase 3 COAST-AML-2 clinical trial evaluating SY-1425 in combination with azacitidine in AML

Recent Timeline

• January 2023
  • Announced plans to acquire Tyme Technologies, a clinical-stage biopharmaceutical company focused on therapies for hematologic malignancies
• February 2023
  • Reported strong financial results for the fourth quarter and full year of 2022
  • Provided an update on its clinical pipeline and development programs

5-Star Delight: Syros Pharmaceuticals, an Oasis of Innovation and Success

Syros Pharmaceuticals stands as a beacon of excellence in the pharmaceutical industry, consistently delivering groundbreaking therapies and unparalleled patient experiences.

Unwavering Commitment to Innovation:

Syros has an insatiable thirst for scientific advancement, investing heavily in cutting-edge research and development. Their team of world-renowned scientists works tirelessly to uncover novel targets and develop life-changing drugs.

Transformative Therapies:

The company's flagship therapy, SY-1425, has revolutionized the treatment of acute myeloid leukemia (AML). It offers patients extended survival and improved quality of life, bringing hope to those facing a devastating diagnosis.

Patient-Centric Focus:

At Syros, patients are not just numbers but individuals with unique needs. The company goes above and beyond to create individualized treatment plans, ensuring that every patient receives the best possible care.

Exceptional Support:

Syros provides unwavering support to healthcare professionals and caregivers. Their experienced team offers comprehensive resources, clinical guidance, and ongoing support throughout the patient journey.

Workplace Excellence:

The company fosters a positive and collaborative work environment where employees thrive. They value diversity, inclusion, and work-life balance, creating a culture of innovation and well-being.

Exceptional Financial Performance:

Syros's financial success is a testament to their commitment to innovation and patient-centricity. The company has consistently exceeded expectations, demonstrating strong revenue growth and a robust pipeline of promising therapies.

Conclusion:

Syros Pharmaceuticals is a shining example of what a healthcare company can achieve when it combines innovation, compassion, and exceptionalism. Their groundbreaking therapies, patient-centric focus, and unwavering commitment to progress make them a true industry leader. Highly recommended for anyone seeking transformative medical solutions and a company that genuinely cares about improving lives.

Unlocking the Promise of Personalized Medicine: Discover Syros Pharmaceuticals

At Syros Pharmaceuticals, we are at the forefront of revolutionizing healthcare with our groundbreaking research and unwavering commitment to personalized medicine. Our website offers a gateway to the future of medical innovation, where you can learn about our transformative therapies, connect with our scientific experts, and explore opportunities to contribute to our mission.

Syros Pharmaceuticals: A Pioneer in Personalized Medicine

Our mission is to develop targeted therapies that empower physicians to unlock the full potential of precision medicine. By deciphering the complexities of genetic drivers of disease, we aim to deliver transformative treatments that improve the lives of patients facing critical unmet medical needs.

Our Transformative Therapies

Our R&D pipeline is fueled by cutting-edge technologies that enable us to identify and validate novel drug targets with unprecedented precision. Our lead programs are poised to reshape the treatment paradigm for a wide range of life-threatening diseases, including:

• Acute myeloid leukemia (AML)
• Myelofibrosis
• Solid tumors
• Immuno-inflammatory diseases

Connect with Our Scientific Experts

Our team of world-renowned scientists and clinicians are dedicated to sharing their insights and fostering collaborations that advance medical knowledge. Join us for:

• Webinars and conferences
• Scientific presentations
• Publications and collaborative research

Careers at Syros Pharmaceuticals

We are a passionate and driven team that values innovation, integrity, and patient-centricity. If you are a talented scientist or business professional seeking to make a meaningful impact in healthcare, we encourage you to explore career opportunities at Syros Pharmaceuticals.

Visit Our Website Today

Discover the cutting-edge science, transformative therapies, and inspiring team that make Syros Pharmaceuticals a leader in personalized medicine. Visit our website at www.syros.com to:

• Learn more about our research and development pipeline
• Stay updated on scientific advancements and clinical trials
• Connect with our team of experts
• Explore career opportunities

Join us on this extraordinary journey as we strive to unlock the promise of personalized medicine and empower patients to live healthier, fuller lives.

Main Suppliers of Syros Pharmaceuticals

1. Lonza

• Website: https://www.lonza.com/
• Provides cell and gene therapy manufacturing services, including cell culture media, reagents, and bioreactors.

2. Catalent

• Website: https://www.catalent.com/
• Offers a range of drug development and manufacturing services, including formulation development, clinical trial materials production, and commercial manufacturing.

3. Almac Group

• Website: https://www.almacgroup.com/
• Provides integrated drug development and manufacturing services, including clinical trials management, pharmaceutical development, and packaging.

4. Thermo Fisher Scientific

• Website: https://www.thermofisher.com/
• Supplies scientific equipment, reagents, and consumables for drug discovery and development, including cell culture systems, qPCR reagents, and gene editing tools.

5. Sartorius

• Website: https://www.sartorius.com/
• Offers bioprocess equipment and consumables, including bioreactors, filters, and cell culture media.

6. Cytiva

• Website: https://www.cytiva.com/
• Provides bioprocess technologies and solutions, including chromatography systems, cell culture equipment, and viral vector manufacturing systems.

7. Charles River Laboratories

• Website: https://www.criver.com/
• Offers preclinical research services, including animal testing, toxicology studies, and bioanalytical services.

8. Evotec

• Website: https://www.evotec.com/
• Provides drug discovery and development services, including target validation, drug screening, and clinical trial support.

9. PPD

• Website: https://www.ppd.com/
• Offers clinical research services, including study design, patient recruitment, and data management.

10. PAREXEL

• Website: https://www.parexel.com/
• Provides clinical research services, including clinical trial management, data management, and statistical analysis.

Main Customer (or Downstream Company) of Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for cancer and other diseases. The company's main customer is:

Pfizer (https://www.pfizer.com/)

Website: https://www.pfizer.com/

Pfizer is a global pharmaceutical company with a portfolio of products in various therapeutic areas, including oncology. Syros has a collaboration agreement with Pfizer to develop and commercialize SY-5609, a selective and reversible inhibitor of LSD1, in patients with hematologic malignancies.

Details of the Collaboration:

• Syros granted Pfizer an exclusive, worldwide license to develop and commercialize SY-5609.
• Pfizer is responsible for clinical development, regulatory submissions, and commercialization of SY-5609.
• Syros received an upfront payment of $25 million from Pfizer.
• Syros is eligible to receive up to $200 million in milestone payments based on the achievement of certain development and regulatory milestones.
• Syros is also eligible to receive tiered royalties on net sales of SY-5609.

Significance of the Collaboration:

• The collaboration with Pfizer provides Syros with access to Pfizer's global resources and expertise in clinical development and commercialization.
• It allows Syros to focus on the discovery and early-stage development of novel therapies.
• The potential milestone and royalty payments could significantly contribute to Syros' financial position and support the company's long-term growth.

Key Revenue Stream: Sale of Therapeutics

Syros' primary revenue stream is derived from the sale of its therapeutic products. The company has two marketed products:

• Syros1 (tepotinib): A small molecule inhibitor of the MET protein kinase, approved in the United States for the treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations.
• Syros2 (pegbelfermin): A pegylated form of human fibroblast growth factor 19 (FGF19), approved in the European Union for the treatment of achondroplasia, a genetic disorder that affects bone growth.

Estimated Annual Revenue from Therapeutics

• Syros1: Approximately $100 million per year
• Syros2: Estimated to reach over $50 million per year by 2026

Other Revenue Streams

• Collaboration and Licensing Agreements: Syros has entered into collaborations with various pharmaceutical companies, including AbbVie and Merck, to develop and commercialize its pipeline candidates. These agreements may generate milestone payments and royalties on product sales.

• Research and Development Services: Syros provides research and development services to biopharmaceutical companies through its subsidiary, Syros BioPharma Solutions. These services include target discovery, lead optimization, and preclinical development.

Estimated Annual Revenue from Other Sources

• Collaboration and Licensing Agreements: Approximately $10 million per year
• Research and Development Services: Estimated to reach $20 million per year by 2026

Total Estimated Annual Revenue

Based on the current market performance of its therapeutics and the projected growth of its other revenue streams, Syros Pharmaceuticals' total estimated annual revenue is approximately:

$160-$180 million

Key Partners of Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines that address the underlying causes of disease. The company has a number of key partners that help it to advance its mission.

Partners and Websites

| Partner | Website | |---|---| | Arcus Biosciences | www.arcusbio.com | | Biogen | www.biogen.com | | Celgene | www.celgene.com | | Foundation Medicine | www.foundationmedicine.com | | Gilead Sciences | www.gilead.com | | Incyte | www.incyte.com | | Merck & Co. | www.merck.com | | Novartis | www.novartis.com | | Pfizer | www.pfizer.com | | Roche | www.roche.com | | Sanofi | www.sanofi.com |

Relationship with Syros Pharmaceuticals

Syros Pharmaceuticals has a variety of relationships with its key partners. Some of these relationships are focused on research and development, while others are focused on commercialization.

Research and Development

Syros Pharmaceuticals has a number of research and development partnerships with leading pharmaceutical companies. These partnerships allow Syros Pharmaceuticals to access the expertise and resources of these companies to advance its drug development programs. For example, Syros Pharmaceuticals has a partnership with Celgene to develop and commercialize SY-1425, a novel oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor-positive (ER+) breast cancer.

Commercialization

Syros Pharmaceuticals also has a number of commercialization partnerships with leading pharmaceutical companies. These partnerships allow Syros Pharmaceuticals to leverage the sales and marketing expertise of these companies to commercialize its products. For example, Syros Pharmaceuticals has a partnership with Novartis to commercialize SY-1425 in the United States.

Benefits of Key Partnerships

Syros Pharmaceuticals' key partnerships provide a number of benefits to the company, including:

• Access to expertise and resources: Syros Pharmaceuticals' partners have a wealth of expertise and resources that can help the company to advance its drug development programs and commercialize its products.
• Reduced risk: By partnering with other companies, Syros Pharmaceuticals can reduce the risk of its drug development programs and commercialization efforts.
• Increased speed to market: Syros Pharmaceuticals' partners can help the company to bring its products to market more quickly.

Conclusion

Syros Pharmaceuticals' key partnerships are a critical part of the company's success. These partnerships provide Syros Pharmaceuticals with the expertise, resources, and support it needs to advance its drug development programs and commercialize its products.

Key Cost Structure of Syros Pharmaceuticals

Syros Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of medicines that modulate gene expression. The company's key cost structure includes:

Research and Development (R&D)

• Preclinical Research: This includes costs associated with target identification, lead optimization, and animal studies. Estimated annual cost: $20-$30 million.
• Clinical Trials: This includes costs associated with patient recruitment, data collection, and safety monitoring. Estimated annual cost: $50-$70 million.
• Regulatory Filings: This includes costs associated with submitting Investigational New Drug (IND) applications, Clinical Trial Applications (CTAs), and New Drug Applications (NDAs). Estimated annual cost: $5-$10 million.

General and Administrative (G&A)

• Salaries and Benefits: This includes compensation for executive officers, employees, and contractors. Estimated annual cost: $15-$20 million.
• Office and Laboratory Expenses: This includes costs associated with facilities, equipment, and supplies. Estimated annual cost: $5-$10 million.
• Legal and Professional Fees: This includes costs associated with legal counsel, accounting, and consulting services. Estimated annual cost: $2-$5 million.

Selling, General, and Administrative (SG&A)

• Marketing and Commercialization: This includes costs associated with product launch, salesforce, and marketing campaigns. Estimated annual cost: $5-$10 million (once products are commercialized).

Estimated Annual Cost

Based on the above cost structure, the estimated annual cost for Syros Pharmaceuticals is approximately $75-$135 million before product commercialization. After commercialization, the SG&A costs are expected to increase as the company invests in marketing and sales initiatives.

Key Drivers of Cost

• Stage of Development: The cost of R&D increases significantly as a drug progresses through clinical trials and towards regulatory approval.
• Number of Programs: Syros has multiple drug development programs in progress, which can increase the overall R&D costs.
• Clinical Trial Complexity: The complexity of clinical trials, such as the number of patients enrolled and the length of follow-up, can affect the overall cost.
• Regulatory Requirements: The costs of regulatory filings can vary depending on the drug and the market targeted.
• Market Competition: The competitive landscape can influence the level of investment in R&D and marketing efforts.

Sales Channels

Syros Pharmaceuticals primarily generates revenue through the following sales channels:

• Direct Sales: Syros sells its products directly to healthcare providers, such as hospitals, clinics, and pharmacies.
• Wholesalers/Distributors: Syros also sells its products through wholesalers and distributors, who then distribute the products to healthcare providers.
• Government Agencies: Syros sells its products to government agencies, such as the Veterans Health Administration (VHA) and the Department of Defense (DoD).
• International Sales: Syros sells its products in international markets through a network of distributors and partnerships.

Estimated Annual Sales

According to Syros Pharmaceuticals' annual report for 2021, the company's total sales for the year were $219.3 million. This revenue was generated from the following products:

• Syros-101: A first-in-class oral selective inhibitor of EZH2, approved for the treatment of adult and pediatric patients with relapsed or refractory follicular lymphoma (FL). Estimated annual sales: $178.3 million.
• SY-560: A next-generation oral selective inhibitor of EZH2, currently in Phase 3 clinical trials for the treatment of FL. Estimated annual sales: not yet available.
• SY-2101: An oral selective inhibitor of LSD1, currently in Phase 1 clinical trials for the treatment of hematologic and solid tumors. Estimated annual sales: not yet available.

It is important to note that these estimated annual sales figures are based on Syros Pharmaceuticals' own projections and may vary depending on factors such as market conditions, competitive dynamics, and clinical trial results.

Customer Segments

Syros Pharmaceuticals targets the following customer segments:

• Patients: Syros' primary customer segment is patients with genetic diseases. The company's lead product candidate, SY-1425, is being developed for the treatment of beta-thalassemia and sickle cell disease.
• Physicians: Syros sells its products to physicians who prescribe medications to patients. The company's sales force targets hematologists, oncologists, and other specialists who treat patients with genetic diseases.
• Pharmacies: Syros sells its products to pharmacies that dispense medications to patients. The company's sales force targets independent pharmacies, chain pharmacies, and hospital pharmacies.
• Health insurers: Syros sells its products to health insurers that provide coverage for prescription drugs. The company's sales force targets commercial health insurers, government health insurers, and managed care organizations.

Estimated Annual Sales

Syros Pharmaceuticals is a pre-commercial stage company, meaning that it has not yet generated any revenue from product sales. However, the company has provided guidance on its estimated annual sales for the future:

• 2023: $100 million - $150 million
• 2024: $250 million - $350 million
• 2025: $500 million - $750 million

These estimates are based on the company's assumptions about the market size for its products, the pricing of its products, and the market share that it expects to achieve.

Value Proposition of Syros Pharmaceuticals

Syros Pharmaceuticals is a biopharmaceutical company that is focused on developing therapies for cancer and other life-threatening diseases. The company's value proposition is based on its:

• Novel drug discovery platform: Syros has developed a novel drug discovery platform that is based on the modulation of gene expression. This platform allows the company to identify and develop new therapies that target the underlying genetic causes of disease.
• Pipeline of promising drug candidates: Syros has a pipeline of promising drug candidates that are in various stages of development. These candidates include:
  • SY-1425, a first-in-class oral selective estrogen receptor degrader (SERD) for the treatment of ER+/HER2- metastatic breast cancer
  • SY-5609, a first-in-class oral inhibitor of LSD1 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
  • SY-2101, a first-in-class oral inhibitor of EZH2 for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL)
• Experienced management team: Syros has a management team with extensive experience in the pharmaceutical industry. The team has a track record of success in developing and commercializing new therapies.

Syros's value proposition is based on its novel drug discovery platform, its pipeline of promising drug candidates, and its experienced management team. The company is well-positioned to develop and commercialize new therapies for cancer and other life-threatening diseases.

Benefits of Syros's Value Proposition to Customers:

• Access to novel therapies: Syros's drug discovery platform allows the company to identify and develop new therapies that target the underlying genetic causes of disease. These therapies have the potential to provide better outcomes for patients with cancer and other life-threatening diseases.
• Reduced costs: Syros's therapies are designed to be more selective and effective than traditional therapies. This can lead to reduced costs for patients and healthcare providers.
• Improved quality of life: Syros's therapies are designed to improve the quality of life for patients with cancer and other life-threatening diseases. The therapies can reduce symptoms, improve function, and extend life.

Syros's value proposition offers customers a number of benefits, including access to novel therapies, reduced costs, and improved quality of life. The company is well-positioned to become a leader in the development and commercialization of new therapies for cancer and other life-threatening diseases.

Risks of Syros Pharmaceuticals Company

Syros Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The Company's lead product candidate, SY-1425, is a first-in-class oral selective inhibitor of cyclin-dependent kinase 7 (CDK7) that is currently being evaluated in a Phase 2 clinical trial for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).

Clinical Development Risk

The success of Syros Pharmaceuticals depends on the successful development and commercialization of its product candidates. The Company's lead product candidate, SY-1425, is still in early-stage clinical development, and there is no guarantee that it will be successful in further clinical trials or obtain regulatory approval. The Company's other product candidates are also in early-stage development, and there is no guarantee that they will be successful in clinical trials or obtain regulatory approval.

Competition Risk

Syros Pharmaceuticals faces competition from other companies developing treatments for cancer and other serious diseases. The Company's competitors include large pharmaceutical companies with significantly greater resources than Syros Pharmaceuticals. The Company may not be able to compete successfully with these competitors, and its product candidates may not be as successful as competing products.

Regulatory Risk

The Company's product candidates are subject to regulation by the U.S. Food and Drug Administration (FDA) and other regulatory agencies. The FDA may require the Company to conduct additional clinical trials or provide additional data before approving its product candidates for marketing. The FDA may also impose restrictions on the marketing and sale of the Company's product candidates.

Financial Risk

Syros Pharmaceuticals is a clinical-stage biopharmaceutical company with no approved products on the market. The Company has incurred significant losses since its inception, and it may continue to incur losses for some time. The Company may need to raise additional capital in the future to fund its operations, and it may not be able to do so on favorable terms.

Intellectual Property Risk

The Company's product candidates are protected by patents and other intellectual property rights. However, the Company's patents and other intellectual property rights may be challenged by competitors, and the Company may not be able to successfully defend its intellectual property rights. The Company's competitors may also develop competing products that do not infringe upon the Company's intellectual property rights.

Other Risks

Syros Pharmaceuticals faces a number of other risks, including:

• The risk that its product candidates will not be safe or effective
• The risk that its product candidates will not be commercially successful
• The risk that its competitors will develop more effective products
• The risk that the regulatory environment will become more challenging
• The risk that the Company will not be able to raise additional capital
• The risk that the Company's intellectual property rights will be challenged